| abstract |
The present invention relates to isoxazolines (I) useful as selective αia/αid adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and/or lower urinary tract symptoms as well as to pharmaceutical compositions comprising said compounds, processes to prepare these compounds, and the use of these compounds as αιa/αid adrenoreceptor modulators in a method of treatment.(I) and a form thereof, wherein L is selected from the group consisting of-CH2-; -CO- and -CONH-; Het is heterocyclyl optionally substituted with one, two or three substituents selected from halo, nitro, oxo, C1-6alkyl, C1-6alkyloxy, C1-6 alkyl-CO-, amino, amino mono-substituted with C1-8alkyl, amino di-substituted with C1-6alkyl, amino mono-substituted with ArC1-6alkyl, amino disubstituted with ArC1-6alkyl, Ar, Ar-CO, Ar-oxy, and Ar-SO2; Ar is selected from pyridinyl, phenyl and phenyl substituted with one or more substituents selected from halo, C1-6alkyl, and C1-6alkyloxy; with the proviso that 1-[[,5-dihydro-5-[[4-[2-(1- methylethoxy) phenyl]-1-piperazinyl]methyl]-3-isoxazolyl]methyl]-2-piperidone is not included |